Skip to main content
Funded Studies

John H. Streiff, PhD

Chief Chemistry Officer at DiscoveryBioMed, Inc.

Location: Birmingham, AL United States

Dr. John Streiff is chief chemistry officer of DiscoveryBioMed, Inc. (DBM), a biotechnology company in Birmingham, Alabama that is focused on leveraging diseased and healthy human cells as platform technologies for ‘humanized’ drug discovery. Dr. Streiff leads DBM’s cell-based drug discovery projects by deploying its compound library of 75,000 compounds accumulated from seven different commercial vendors that maximizes chemical diversity of small molecules. Dr. Streiff leads the high-throughput screening and validation assays together with the DBM biology team, and he performs bioinformatics for ‘hit picking’ as well as cheminformatics to identify and deepen hit-to-lead chemical classes and select ‘best in class’ target-binding scaffolds to virtually screen larger chemical libraries. He also calculates the key chemical metrics that predict human blood-brain barrier (BBB) permeation critical to the development of inhibitors development for Parkinson’s disease. Dr. Streiff has been in this role at DBM for 12 years.

Associated Grants

  • Preclinical Development of Immune-inhibiting Small Molecules as Therapeutics for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.